{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:15:37Z","timestamp":1792012537012,"version":"4.4.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Targeted cancer therapies have been responsible for a dramatic shift in treatment strategies for cancer, and the number of drugs, classes, and indications are continually growing. Neuro-ophthalmic complications of these medications are an uncommon but important subset of adverse events which profoundly impact vision. This review aims to collate studies and reports of known neuro-ophthalmic complications of targeted therapies and describe their management.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The anti-cancer drugs included in the review were any drugs targeting specific molecules involved in the cancer disease process. PubMed, EMBASE, and Web of Science were searched using the generic names of each drug and keywords of neuro-ophthalmic conditions. The prescribing information published by the US Food and Drug Administration (FDA) for each drug was also reviewed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Several classes of targeted anti-cancer drugs were found to cause neuro-ophthalmic adverse effects. Immune checkpoint inhibitors are responsible for a raft of immune-related adverse events such as optic neuritis, ischemic optic neuropathy, PRES, and myasthenia gravis. Therapies with anti-VEGF activity can provoke posterior reversible leukoencephalopathy, which commonly presents with visual loss and can be fatal if not treated promptly. Inhibitors of BCR-ABL1, VEGF, ALK, and proteasomes have all been linked to optic nerve disorders which can have debilitating consequences for vision.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The neuro-ophthalmic complications of modern anti-cancer drugs can limit or necessitate the withdrawal of these life-prolonging medications. Ophthalmologists should be alert for neuro-ophthalmic complications in these medications to facilitate prompt diagnosis and treatment and reduce the risk of severe and permanent consequences.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-023-06350-4","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T11:02:18Z","timestamp":1707735738000},"page":"2269-2281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neuro-ophthalmic complications of modern anti-cancer drugs"],"prefix":"10.1007","volume":"262","author":[{"given":"Joshua A.","family":"Oskam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen V.","family":"Danesh-Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"6350_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","volume":"113","author":"H Lee","year":"2021","unstructured":"Lee H, Basso IN, Kim DDH (2021) Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol 113:632\u2013641. https:\/\/doi.org\/10.1007\/s12185-021-03126-6","journal-title":"Int J Hematol"},{"key":"6350_CR2","unstructured":"Novartis Pharmaceuticals Corporation (2008) Gleevec (Imatinib mesylate) [package insert]. U.S. Food and Drug Administration Website.\u00a0\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021588s024lbl.pdf. Accessed 1 Mar 2022"},{"key":"6350_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11912-021-01165-0","volume":"24","author":"C Serrano","year":"2022","unstructured":"Serrano C, Bauer S (2022) New tyrosine kinase inhibitors for the treatment of gastrointestinal stromal tumors. Curr Oncol Rep 24:151\u2013159. https:\/\/doi.org\/10.1007\/s11912-021-01165-0","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"6350_CR4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.leukres.2007.10.016","volume":"32","author":"M Breccia","year":"2008","unstructured":"Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A, Alimena G (2008) Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res 32(7):1022\u20131025","journal-title":"Leuk Res"},{"key":"6350_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10792-007-9038-9","volume":"27","author":"K Govind Babu","year":"2007","unstructured":"Govind Babu K, Attili VS, Bapsy PP, Anupama G (2007) Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 27:43\u201344. https:\/\/doi.org\/10.1007\/s10792-007-9038-9","journal-title":"Int Ophthalmol"},{"key":"6350_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1177\/1352458519892914","volume":"26","author":"DL Rotstein","year":"2020","unstructured":"Rotstein DL, Sawicka K, Bharatha A, Montalban X, Lipton JH (2020) CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: a report of two cases. Mult Scler 26:1121\u20131124. https:\/\/doi.org\/10.1177\/1352458519892914","journal-title":"Mult Scler"},{"key":"6350_CR7","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1080\/10428194.2019.1633635","volume":"60","author":"H Rafei","year":"2019","unstructured":"Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M (2019) Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma 60:3292\u20133295. https:\/\/doi.org\/10.1080\/10428194.2019.1633635","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"6350_CR8","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1097\/OPX.0b013e318269111d","volume":"89","author":"C DeLuca","year":"2012","unstructured":"DeLuca C, Shenouda-Awad N, Haskes C, Wrzesinski S (2012) Imatinib mesylate (Gleevec) induced unilateral optic disc edema. Optomet Vis Sci 89(10):e16-22","journal-title":"Optomet Vis Sci"},{"issue":"10","key":"6350_CR9","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/ccr3.1137","volume":"5","author":"M Napolitano","year":"2017","unstructured":"Napolitano M, Santoro M, Mancuso S, Carlisi M, Raso S, Tarantino G, Accurso V, Siragusa S (2017) Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate. Clin Case Rep 5(10):1573\u20131575","journal-title":"Clin Case Rep"},{"issue":"4","key":"6350_CR10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10384-008-0561-7","volume":"52","author":"SI Kwon","year":"2008","unstructured":"Kwon SI, Lee DH, Kim YJ (2008) Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol 52(4):331\u2013333","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"6350_CR11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3345\/kjp.2013.56.8.343","volume":"56","author":"HJ Oh","year":"2013","unstructured":"Oh HJ, Cho MS, Lee JW, Jang PS, Chung NG, Cho B, Kim HK (2013) Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia. Korean J Pediatr 56(8):343\u2013350","journal-title":"Korean J Pediatr"},{"key":"6350_CR12","unstructured":"Bristol-Myers Squibb Company (2010) Sprycel (Dasatinib) [package insert]. U.S. Food and Drug Administration Website.\u00a0\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf Accessed 1 Mar 2022"},{"issue":"3","key":"6350_CR13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.sjopt.2014.12.004","volume":"29","author":"KS Monge","year":"2015","unstructured":"Monge KS, Galvez-Ruiz A, Alvarez-Carron A, Quijada C, Matheu A (2015) Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthalmol 29(3):227\u2013231","journal-title":"Saudi J Ophthalmol"},{"key":"6350_CR14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.leukres.2015.11.008","volume":"40","author":"M Breccia","year":"2016","unstructured":"Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, D\u2019Adda M, Maggi A, Sgherza N, Russo-Rossi A, Pregno P, Castagnetti F, Iurlo A, Latagliata R, Cedrone M, Di Renzo N, Sora F, Rege-Cambrin G, La Nasa G, Scortechini AR, Greco G, Franceschini L, Sica S, Bocchia M, Crugnola M, Orlandi E, Guarini A, Specchia G, Rosti G, Saglio G, Alimena G (2016) Dasatinib first-line: multicentric Italian experience outside clinical trials. Leuk Res 40:24\u201329","journal-title":"Leuk Res"},{"key":"6350_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/2047-783x-16-5-206","volume":"16","author":"M Schlemmer","year":"2011","unstructured":"Schlemmer M, Bauer S, Sch\u00fctte R, Hartmann JT, Bokemeyer C, Hosius C, Reichardt P (2011) Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial. Eur J Med Res 16:206\u2013212. https:\/\/doi.org\/10.1186\/2047-783x-16-5-206","journal-title":"Eur J Med Res"},{"key":"6350_CR16","first-page":"2929","volume":"61","author":"K Pietras","year":"2001","unstructured":"Pietras K, Ostman A, Sj\u00f6quist M, Buchdunger E, Reed RK, Heldin CH, Rubin K (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929\u20132934","journal-title":"Cancer Res"},{"key":"6350_CR17","first-page":"1599","volume":"15","author":"SK Biswas","year":"2009","unstructured":"Biswas SK, Zhao Y, Sandirasegarane L (2009) Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase\/Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis 15:1599\u20131610","journal-title":"Mol Vis"},{"issue":"4","key":"6350_CR18","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10072-020-04604-1","volume":"42","author":"C Demichelis","year":"2021","unstructured":"Demichelis C, Balestra A, Lapucci C, Zuppa A, Grisanti SG, Prada V, Pesce G, Grasso I, Queirolo P, Schenone A, Benedetti L, Grandis M (2021) Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature. Neurol Sci 42(4):1405\u20131409","journal-title":"Neurol Sci"},{"key":"6350_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clim.2017.03.003","volume":"179","author":"S Kohler","year":"2017","unstructured":"Kohler S, Keil TOP, Hoffmann S, Swierzy M, Ismail M, R\u00fcckert JC, Alexander T, Meisel A (2017) CD4(+) FoxP3(+) T regulatory cell subsets in myasthenia gravis patients. Clin Immunol 179:40\u201346. https:\/\/doi.org\/10.1016\/j.clim.2017.03.003","journal-title":"Clin Immunol"},{"key":"6350_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.matbio.2015.04.004","volume":"44\u201346","author":"EI Deryugina","year":"2015","unstructured":"Deryugina EI, Quigley JP (2015) Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol 44\u201346:94\u2013112. https:\/\/doi.org\/10.1016\/j.matbio.2015.04.004","journal-title":"Matrix Biol"},{"key":"6350_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/practneurol-2021-003194","volume":"22","author":"JD Triplett","year":"2022","unstructured":"Triplett JD, Kutlubaev MA, Kermode AG, Hardy T (2022) Posterior reversible encephalopathy syndrome (PRES): diagnosis and management. Pract Neurol 22:183\u2013189. https:\/\/doi.org\/10.1136\/practneurol-2021-003194","journal-title":"Pract Neurol"},{"key":"6350_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/annonc\/mdn713","volume":"20","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20:807\u2013815. https:\/\/doi.org\/10.1093\/annonc\/mdn713","journal-title":"Ann Oncol"},{"key":"6350_CR23","doi-asserted-by":"crossref","unstructured":"Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, Coriat R, Goldwasser F (2011) Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol 1\u20136","DOI":"10.1007\/s11523-011-0201-x"},{"key":"6350_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3174\/ajnr.A0929","volume":"29","author":"WS Bartynski","year":"2008","unstructured":"Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 29:1043\u20131049. https:\/\/doi.org\/10.3174\/ajnr.A0929","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"6350_CR25","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.4103\/1673-5374.270420","volume":"15","author":"J Wong So","year":"2020","unstructured":"Wong So J, Largeau B, Beau-Salinas F, Ehrmann S, Magni C, Meunier J (2020) Pazopanib-induced posterior reversible encephalopathy syndrome with possible syndrome of inappropriate secretion of antidiuretic hormone: an incidental or pathophysiological association? Neural Regen Res 15(6):1166\u20131168","journal-title":"Neural Regen Res"},{"key":"6350_CR26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2016.07.008","volume":"66","author":"C Tlemsani","year":"2016","unstructured":"Tlemsani C, Mir O, Psimaras D, Vano YA, Ducreux M, Escudier B, Rousseau B, Loirat D, Ceccaldi B, Andre T, Goldwasser F, Ricard D (2016) Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: clinical experience in Paris University Hospitals. Eur J Cancer 66:75\u201382","journal-title":"Eur J Cancer"},{"key":"6350_CR27","unstructured":"Genentech, Inc. Sprycel (Bevacizumab) [package insert]. U.S. Food and Drug Administration Website. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125085s301lbl.pdf Accessed 1 Mar 2022"},{"issue":"7","key":"6350_CR28","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1634\/theoncologist.2014-0149","volume":"20","author":"S Singer","year":"2015","unstructured":"Singer S, Grommes C, Reiner AS, Rosenblum MK, DeAngelis LM (2015) Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist 20(7):806\u2013811","journal-title":"Oncologist"},{"key":"6350_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/qjmed\/hcr139","volume":"105","author":"RC Seet","year":"2012","unstructured":"Seet RC, Rabinstein AA (2012) Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM 105:69\u201375. https:\/\/doi.org\/10.1093\/qjmed\/hcr139","journal-title":"QJM"},{"issue":"10","key":"6350_CR30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archneur.63.10.1475","volume":"63","author":"JA Allen","year":"2006","unstructured":"Allen JA, Adlakha A, Bergethon PR (2006) Reversible posterior leukoencephalopathy syndrome after bevacizumab\/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 63(10):1475\u20131478","journal-title":"Arch Neurol"},{"key":"6350_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1442-9071.2007.01658.x","volume":"36","author":"S Peter","year":"2008","unstructured":"Peter S, Hausmann N, Schuster A, Boehm HF (2008) Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab. Clin Exp Ophthalmol 36:94\u201396. https:\/\/doi.org\/10.1111\/j.1442-9071.2007.01658.x","journal-title":"Clin Exp Ophthalmol"},{"key":"6350_CR32","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1078155215611048","volume":"22","author":"MK Ery\u0131lmaz","year":"2016","unstructured":"Ery\u0131lmaz MK, Mutlu H, Salim DK, Musri FY, Co\u015fkun H (2016) Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. J Oncol Pharm Pract 22:806\u2013810. https:\/\/doi.org\/10.1177\/1078155215611048","journal-title":"J Oncol Pharm Pract"},{"issue":"26","key":"6350_CR33","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1200\/JCO.2011.38.8942","volume":"30","author":"F Sclafani","year":"2012","unstructured":"Sclafani F, Giuseppe G, Mezynksi J, Collins C, Crown J (2012) Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer. J Clin Oncol 30(26):e257\u2013e259","journal-title":"J Clin Oncol"},{"key":"6350_CR34","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJMc052954","volume":"354","author":"P Glusker","year":"2006","unstructured":"Glusker P, Recht L, Lane B (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980\u2013982. https:\/\/doi.org\/10.1056\/NEJMc052954. (discussion 980-982)","journal-title":"N Engl J Med"},{"key":"6350_CR35","first-page":"80","volume":"17","author":"PC Lau","year":"2011","unstructured":"Lau PC, Paunipagar B (2011) Posterior reversible encephalopathy syndrome with bevacizumab. Hong Kong Med J 17:80\u201381","journal-title":"Hong Kong Med J"},{"issue":"5","key":"6350_CR36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/jgh.12569","volume":"29","author":"N Goto","year":"2014","unstructured":"Goto N, Mimura J (2014) Gastrointestinal: Bevacizumab-induced reversible posterior leukoencephalopathy syndrome in patient with rectal cancer. J Gastroenterol Hepatol (Australia) 29(5):895\u2013895","journal-title":"J Gastroenterol Hepatol (Australia)"},{"key":"6350_CR37","doi-asserted-by":"publisher","unstructured":"Salmi N, Elghissassi I, Bellahammou K, Lakhdissi A, Mrabti H, Errihani H (2014) Atypical reversible leucoencephalopathy syndrome after bevacizumab\/folfox regimen for metastatic colon cancer. Case Rep Oncol Med 2014. https:\/\/doi.org\/10.1155\/2014\/391256","DOI":"10.1155\/2014\/391256"},{"key":"6350_CR38","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1007\/s00415-013-6866-6","volume":"260","author":"R Dersch","year":"2013","unstructured":"Dersch R, Stich O, Goller K, Meckel S, Dechent F, Doostkam S, Weiller C, Bardutzky J (2013) Atypical posterior reversible encephalopathy syndrome associated with chemotherapy with bevacizumab, gemcitabine and cisplatin. J Neurol 260:1406\u20131407. https:\/\/doi.org\/10.1007\/s00415-013-6866-6","journal-title":"J Neurol"},{"key":"6350_CR39","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.2147\/ott.S166605","volume":"11","author":"X Li","year":"2018","unstructured":"Li X, Chai J, Wang Z, Lu L, Zhao Q, Zhou J, Ju F (2018) Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review. Onco Targets Ther 11:4407\u20134411. https:\/\/doi.org\/10.2147\/ott.S166605","journal-title":"Onco Targets Ther"},{"issue":"22","key":"6350_CR40","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1212\/WNL.0b013e3181c3fd00","volume":"73","author":"JH Sherman","year":"2009","unstructured":"Sherman JH, Aregawi DG, Lai A, Fathallah-Shaykh HM, Bierman PJ, Linsky K, Larner JM, Newman SA, Schiff D (2009) Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 73(22):1924\u20131926","journal-title":"Neurology"},{"issue":"6","key":"6350_CR41","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(14)70110-X","volume":"15","author":"PG Corrie","year":"2014","unstructured":"Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P (2014) Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): Preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol 15(6):620\u2013630","journal-title":"Lancet Oncol"},{"issue":"12","key":"6350_CR42","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-11-0120","volume":"17","author":"JJ Vredenburgh","year":"2011","unstructured":"Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon IJE, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS (2011) The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17(12):4119\u20134124","journal-title":"Clin Cancer Res"},{"key":"6350_CR43","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1111\/ajco.12129","volume":"12","author":"M Momeni","year":"2016","unstructured":"Momeni M, Veras L, Zakashansky K (2016) Bevacizumab-induced transient sixth nerve palsy in ovarian cancer: a case report. Asia Pac J Clin Oncol 12:e196-198. https:\/\/doi.org\/10.1111\/ajco.12129","journal-title":"Asia Pac J Clin Oncol"},{"key":"6350_CR44","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1177\/10781552211066888","volume":"28","author":"E De\u011ferli","year":"2022","unstructured":"De\u011ferli E, Alkan G, \u00d6zta\u015f N, Bedir \u015e, Derin S, Demirci NS (2022) Bevacizumab-induced isolated oculomotor nerve palsy in glioblastoma multiforme. J Oncol Pharm Pract 28:746\u2013749. https:\/\/doi.org\/10.1177\/10781552211066888","journal-title":"J Oncol Pharm Pract"},{"key":"6350_CR45","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, J\u00e4nne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1006448","journal-title":"N Engl J Med"},{"key":"6350_CR46","unstructured":"Pfizer Labs. Xalkori (Crizotinib) [package insert]. U.S. Food and Drug Administration Website. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202570s030lbl.pdf. Accessed 1 Mar 2022"},{"issue":"10","key":"6350_CR47","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","volume":"13","author":"DR Camidge","year":"2012","unstructured":"Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SHI, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Janne PA, Costa DB, Shapiro GI, LoRusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13(10):1011\u20131019","journal-title":"Lancet Oncol"},{"key":"6350_CR48","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crin\u00f3 L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, J\u00e4nne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385\u20132394. https:\/\/doi.org\/10.1056\/NEJMoa1214886","journal-title":"N Engl J Med"},{"key":"6350_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/toxsci\/kfu213","volume":"143","author":"CN Liu","year":"2015","unstructured":"Liu CN, Mathialagan N, Lappin P, Fortner J, Somps C, Seitis G, Johnson TR, Hu W, Matsumoto D (2015) Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition. Toxicol Sci 143:116\u2013125. https:\/\/doi.org\/10.1093\/toxsci\/kfu213","journal-title":"Toxicol Sci"},{"key":"6350_CR50","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1200\/jco.2013.49.1985","volume":"33","author":"SG Chun","year":"2015","unstructured":"Chun SG, Iyengar P, Gerber DE, Hogan RN, Timmerman RD (2015) Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation. J Clin Oncol 33:e25-26. https:\/\/doi.org\/10.1200\/jco.2013.49.1985","journal-title":"J Clin Oncol"},{"key":"6350_CR51","unstructured":"Novartis Pharmaceuticals Corporation (2017) Zykadia (Ceritinib) [package insert]. U.S. Food and Drug Administration Website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205755s009lbl.pdf. Accessed 1 Mar 2022"},{"key":"6350_CR52","unstructured":"Pfizer Labs (2021) Lorbrena (Lorlatinib) [package insert]. U.S. Food and Drug Administration Website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210868s004lbl.pdf. Accessed 1 Mar 2022"},{"key":"6350_CR53","unstructured":"Genentech USA Inc (2019) Rozlytrek (Entrectinib) [package insert]. U.S. Food and Drug Administration Website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212725s000lbl.pdf. Accessed 1 Mar 2022"},{"key":"6350_CR54","unstructured":"Genentech USA Inc (2017) Alecensa (Alectinib) [package insert]. U.S. Food and Drug Administration Website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208434s003lbl.pdf Accessed 1 Mar 2022"},{"key":"6350_CR55","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","volume":"14","author":"EE Manasanch","year":"2017","unstructured":"Manasanch EE, Orlowski RZ (2017) Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 14:417\u2013433. https:\/\/doi.org\/10.1038\/nrclinonc.2016.206","journal-title":"Nat Rev Clin Oncol"},{"key":"6350_CR56","unstructured":"Millenium Pharmaceuticals, Inc (2008) Velcade (Bortezomib) [package insert]. U.S. Food and Drug Administration Website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021602s015lbl.pdf. Accessed 1 Mar 2022"},{"issue":"4","key":"6350_CR57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/WNO.0000000000000657","volume":"38","author":"JG Chacko","year":"2018","unstructured":"Chacko JG, Behbehani R, Hundley KN, Al-Fanek Y (2018) Bortezomib-associated optic atrophy in two patients with multiple myeloma. J Neuroophthalmol 38(4):473\u2013475","journal-title":"J Neuroophthalmol"},{"key":"6350_CR58","doi-asserted-by":"crossref","unstructured":"Toema B, El-Sweilmeen H, Helmy T (2010) Oculomotor nerve palsy associated with bortezomib in a patient with multiple myeloma: a case report. J Med Case Rep 4(1) (no pagination)","DOI":"10.1186\/1752-1947-4-342"},{"key":"6350_CR59","doi-asserted-by":"publisher","unstructured":"\u0141uczkowska K, Rogi\u0144ska D, Kulig P, Bielikowicz A, Baumert B, Machali\u0144ski B (2022) Bortezomib-induced epigenetic alterations in nerve cells: focus on the mechanisms contributing to the peripheral neuropathy development. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms23052431","DOI":"10.3390\/ijms23052431"},{"key":"6350_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1445-5994.2009.02097.x","volume":"40","author":"E Terwiel","year":"2010","unstructured":"Terwiel E, Hanrahan R, Lueck C, D\u2019Rozario J (2010) Reversible posterior encephalopathy syndrome associated with bortezomib. Intern Med J 40:69\u201371. https:\/\/doi.org\/10.1111\/j.1445-5994.2009.02097.x","journal-title":"Intern Med J"},{"key":"6350_CR61","doi-asserted-by":"publisher","unstructured":"Kager LM, Kersten MJ, Kloppenborg RP, Van Oers R, Van den Born BJ (2009) Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma. BMJ Case Rep 2009. https:\/\/doi.org\/10.1136\/bcr.06.2009.1926","DOI":"10.1136\/bcr.06.2009.1926"},{"key":"6350_CR62","doi-asserted-by":"publisher","unstructured":"Kadhem S, Ebrahem R, Cooper S, Manlove E, Lee R (2017) Status epilepticus and blindness in a patient with carfilzomib-associated posterior reversible encephalopathy syndrome. Cureus 9. https:\/\/doi.org\/10.7759\/cureus.1041","DOI":"10.7759\/cureus.1041"},{"issue":"2","key":"6350_CR63","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO.2013.49.6166","volume":"34","author":"X Cai","year":"2016","unstructured":"Cai X, Bhattacharyya S, Plitt A, Raibagkar P, LaBuzetta JN, Schleicher SM, Munshi NC, Klein JP (2016) Management of posterior reversible encephalopathy syndrome induced by carfilzomib in a patient with multiple myeloma. J Clin Oncol 34(2):e1\u2013e5","journal-title":"J Clin Oncol"},{"issue":"16","key":"6350_CR64","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2169\/internalmedicine.53.2383","volume":"53","author":"CH Ho","year":"2014","unstructured":"Ho CH, Lo CP, Tu MC (2014) Bortezomib-induced posterior reversible encephalopathy syndrome: clinical and imaging features. Intern Med 53(16):1853\u20131857","journal-title":"Intern Med"},{"key":"6350_CR65","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954. https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nature"},{"key":"6350_CR66","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/annonc\/mdz114","volume":"30","author":"S Engel","year":"2019","unstructured":"Engel S, Luessi F, Henning B, Bittner S, Loquai C, Zipp F (2019) Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome. Ann Oncol 30:1014\u20131016. https:\/\/doi.org\/10.1093\/annonc\/mdz114","journal-title":"Ann Oncol"},{"key":"6350_CR67","unstructured":"Genentech USA Inc (2017) Zelboraf (Vemurafenib) [package insert]. U.S. Food and Drug Administration Website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202429s016lbl.pdf Accessed 1 Mar 2022."},{"key":"6350_CR68","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1078155214543212","volume":"21","author":"A Khurana","year":"2015","unstructured":"Khurana A, Dasanu CA (2015) Posterior reversible encephalopathy syndrome due to targeted agents: vemurafinib among suspects! J Oncol Pharm Pract 21:443\u2013450. https:\/\/doi.org\/10.1177\/1078155214543212","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"6350_CR69","first-page":"136","volume":"18","author":"MI Stefanou","year":"2020","unstructured":"Stefanou MI, Gepfner-Tuma I, Brendle C, Kowarik M, Meiwes A, Eigentler T, Muller A, Garbe C, Ziemann U, Tabatabai G, Forschner A (2020) Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy. JDDG - J German Soc Dermatol 18(2):136\u2013139","journal-title":"JDDG - J German Soc Dermatol"},{"issue":"7","key":"6350_CR70","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1212\/WNL.0000000000008860","volume":"94","author":"A Zaloum","year":"2020","unstructured":"Zaloum A, Falet JPR, Elkrief A, Chalk C (2020) Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma. Neurology 94(7):322\u2013323","journal-title":"Neurology"},{"key":"6350_CR71","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2018.08.019","volume":"136","author":"M Kuske","year":"2018","unstructured":"Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, Meier F (2018) Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy. Pharmacol Res 136:151\u2013159. https:\/\/doi.org\/10.1016\/j.phrs.2018.08.019","journal-title":"Pharmacol Res"},{"key":"6350_CR72","doi-asserted-by":"publisher","unstructured":"Najjar MK, Manore SG, Regua AT, Lo HW (2022) Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Genes (Basel) 13. https:\/\/doi.org\/10.3390\/genes13112065","DOI":"10.3390\/genes13112065"},{"key":"6350_CR73","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1038\/sj.onc.1209685","volume":"25","author":"XF Wen","year":"2006","unstructured":"Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr, Le XF (2006) HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25:6986\u20136996. https:\/\/doi.org\/10.1038\/sj.onc.1209685","journal-title":"Oncogene"},{"key":"6350_CR74","unstructured":"Genentech, Inc (2010) Herceptin (Trastuzumab) [package insert]. U.S. Food and Drug Administration Website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5250lbl.pdf Accessed 1 Mar 2022."},{"issue":"6","key":"6350_CR75","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/jop.2018.0019","volume":"34","author":"FT Fraunfelder","year":"2018","unstructured":"Fraunfelder FT, Fraunfelder FW (2018) Oral anti-vascular endothelial growth factor drugs and ocular adverse events. J Ocul Pharmacol Ther 34(6):432\u2013435","journal-title":"J Ocul Pharmacol Ther"},{"key":"6350_CR76","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10072-020-04713-x","volume":"42","author":"S Na","year":"2021","unstructured":"Na S, Kim T (2021) Optic neuritis associated with sunitinib. Neurol Sci 42:1165\u20131167. https:\/\/doi.org\/10.1007\/s10072-020-04713-x","journal-title":"Neurol Sci"},{"issue":"Suppl 1","key":"6350_CR77","doi-asserted-by":"publisher","first-page":"S395","DOI":"10.1007\/s12032-010-9719-5","volume":"28","author":"J Yoong","year":"2011","unstructured":"Yoong J, Chong G, Hamilton K (2011) Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma. Med Oncol 28(Suppl 1):S395-397. https:\/\/doi.org\/10.1007\/s12032-010-9719-5","journal-title":"Med Oncol"},{"key":"6350_CR78","doi-asserted-by":"crossref","unstructured":"Huang YT, Lin CJ, Tsai YY, Hsia NY (2022) Bilateral optic disc edema as a possible complication of cabozantinib use-a case report. Eur J Ophthalmol","DOI":"10.1177\/11206721221078675"},{"key":"6350_CR79","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/annonc\/mdm454","volume":"18","author":"E Kapiteijn","year":"2007","unstructured":"Kapiteijn E, Brand A, Kroep J, Gelderblom H (2007) Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 18:1745\u20131747. https:\/\/doi.org\/10.1093\/annonc\/mdm454","journal-title":"Ann Oncol"},{"key":"6350_CR80","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1365-2125.2010.03893.x","volume":"71","author":"BM Padhy","year":"2011","unstructured":"Padhy BM, Shanmugam SP, Gupta YK, Goyal A (2011) Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Br J Clin Pharmacol 71:777\u2013779. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03893.x","journal-title":"Br J Clin Pharmacol"},{"key":"6350_CR81","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s13760-020-01367-6","volume":"120","author":"N Rifino","year":"2020","unstructured":"Rifino N, Mantero V, Filizzolo MG, Basilico P, Scaccabarozzi C, Arnoffi J, Salmaggi A (2020) Sunitinib associated posterior reversible encephalopathy syndrome in a patient treated for GIST. Acta Neurol Belg 120:995\u2013997. https:\/\/doi.org\/10.1007\/s13760-020-01367-6","journal-title":"Acta Neurol Belg"},{"key":"6350_CR82","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/01658107.2010.539763","volume":"35","author":"FM Dos Reis Sim\u00f5es da Silva","year":"2011","unstructured":"Dos Reis Sim\u00f5es da Silva FM, Burgos P\u00eago PM, HenriquesVendrell MC, de Azevedo Batalha Ferreira Dos Santos Farias MJ, Ribeiro Tim\u00f3teo AC, Martins da Costa MC, Monteiro Barbosa Moreira Cravo IM, Ribeiro Gomes FM (2011) Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report. Neuroophthalmology 35:32\u201337. https:\/\/doi.org\/10.3109\/01658107.2010.539763","journal-title":"Neuroophthalmology"},{"key":"6350_CR83","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1200\/jco.2007.12.8710","volume":"25","author":"G Mart\u00edn","year":"2007","unstructured":"Mart\u00edn G, Bellido L, Cruz JJ (2007) Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25:3559. https:\/\/doi.org\/10.1200\/jco.2007.12.8710","journal-title":"J Clin Oncol"},{"key":"6350_CR84","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/952624","volume":"2014","author":"R Costa","year":"2014","unstructured":"Costa R, Costa R, Costa R, Junior GM, Cartaxo HQ, de Barros AC (2014) Reversible posterior encephalopathy syndrome secondary to sunitinib. Case Rep Oncol Med 2014:952624. https:\/\/doi.org\/10.1155\/2014\/952624","journal-title":"Case Rep Oncol Med"},{"issue":"5","key":"6350_CR85","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1177\/030089161209800525","volume":"98","author":"KH Khan","year":"2012","unstructured":"Khan KH, Fenton A, Murtagh E, McAleer JJA, Clayton A (2012) Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. Tumori 98(5):e139\u2013e142","journal-title":"Tumori"},{"key":"6350_CR86","doi-asserted-by":"crossref","unstructured":"Fukui S, Toyoshima Y, Inoue T, Kagebayashi Y, Samma S (2016) Reversible posterior leukoencephalopathy syndrome developing after restart of sunitinib therapy for metastatic renal cell carcinoma. Case Rep Med 2016 (no pagination)","DOI":"10.1155\/2016\/6852951"},{"key":"6350_CR87","doi-asserted-by":"crossref","unstructured":"Chelis L, Souftas V, Amarantidis K, Xenidis N, Chamalidou E, Dimopoulos P, Michailidis P, Christakidis E, Prassopoulos P, Kakolyris S (2012) Reversible posterior leukoencephalopathy syndrome induced by pazopanib. BMC Cancer 12 (no pagination)","DOI":"10.1186\/1471-2407-12-489"},{"key":"6350_CR88","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s10637-017-0521-5","volume":"36","author":"S Deguchi","year":"2018","unstructured":"Deguchi S, Mitsuya K, Nakasu Y, Hayashi N, Katagiri H, Murata H, Wasa J, Takahashi M, Endo M (2018) Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature. Invest New Drugs 36:346\u2013349. https:\/\/doi.org\/10.1007\/s10637-017-0521-5","journal-title":"Invest New Drugs"},{"issue":"2","key":"6350_CR89","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jcpt.12031","volume":"38","author":"G Asaithambi","year":"2013","unstructured":"Asaithambi G, Peters BR, Hurliman E, Moran BP, Khan AS, Taylor RA (2013) Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma. J Clin Pharm Ther 38(2):175\u2013176","journal-title":"J Clin Pharm Ther"},{"key":"6350_CR90","doi-asserted-by":"publisher","first-page":"140","DOI":"10.18071\/isz.70.0001","volume":"70","author":"BM Arslan","year":"2017","unstructured":"Arslan BM, Bajrami A, Demir E, Cabalar M, Yayla V (2017) Pazopanib induced unilateral posterior reversible encephalopathy syndrome. Ideggyogy Sz 70:140\u2013144. https:\/\/doi.org\/10.18071\/isz.70.0001","journal-title":"Ideggyogy Sz"},{"key":"6350_CR91","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.08.4608","volume":"24","author":"R Govindarajan","year":"2006","unstructured":"Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI (2006) Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43\u20139006. J Clin Oncol 24:e48. https:\/\/doi.org\/10.1200\/jco.2006.08.4608","journal-title":"J Clin Oncol"},{"key":"6350_CR92","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s12032-009-9378-6","volume":"27","author":"E Dogan","year":"2010","unstructured":"Dogan E, Aksoy S, Arslan C, Dede DS, Altundag K (2010) Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol 27:1436\u20131437. https:\/\/doi.org\/10.1007\/s12032-009-9378-6","journal-title":"Med Oncol"},{"key":"6350_CR93","doi-asserted-by":"publisher","unstructured":"Aanes SG, Nieder C, Prytz J, Odeh F (2018) A man in his 50s with neurological symptoms during cancer treatment. Tidsskr Nor Laegeforen 138. https:\/\/doi.org\/10.4045\/tidsskr.18.0096","DOI":"10.4045\/tidsskr.18.0096"},{"key":"6350_CR94","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2169\/internalmedicine.9593-17","volume":"57","author":"Y Osawa","year":"2018","unstructured":"Osawa Y, Gozawa R, Koyama K, Nakayama T, Sagoh T, Sunaga H (2018) Posterior reversible encephalopathy syndrome after lenvatinib therapy in a patient with anaplastic thyroid carcinoma. Intern Med 57:1015\u20131019. https:\/\/doi.org\/10.2169\/internalmedicine.9593-17","journal-title":"Intern Med"},{"key":"6350_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112516","volume":"146","author":"H Alemohammad","year":"2022","unstructured":"Alemohammad H, Najafzadeh B, Asadzadeh Z, Baghbanzadeh A, Ghorbaninezhad F, Najafzadeh A, Safarpour H, Bernardini R, Brunetti O, Sonnessa M, Fasano R, Silvestris N, Baradaran B (2022) The importance of immune checkpoints in immune monitoring: a future paradigm shift in the treatment of cancer. Biomed Pharmacother 146:112516. https:\/\/doi.org\/10.1016\/j.biopha.2021.112516","journal-title":"Biomed Pharmacother"},{"key":"6350_CR96","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19:133\u2013150. https:\/\/doi.org\/10.1038\/s41568-019-0116-x","journal-title":"Nat Rev Cancer"},{"key":"6350_CR97","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","volume":"71","author":"N Okiyama","year":"2022","unstructured":"Okiyama N, Tanaka R (2022) Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol Int 71:169\u2013178. https:\/\/doi.org\/10.1016\/j.alit.2022.01.001","journal-title":"Allergol Int"},{"issue":"3","key":"6350_CR98","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K (2018) Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer. JAMA Oncol 4(3):374\u2013378","journal-title":"JAMA Oncol"},{"key":"6350_CR99","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","volume":"71","author":"YM Cheung","year":"2022","unstructured":"Cheung YM, Wang W, McGregor B, Hamnvik OR (2022) Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother 71:1795\u20131812. https:\/\/doi.org\/10.1007\/s00262-021-03128-7","journal-title":"Cancer Immunol Immunother"},{"key":"6350_CR100","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2020.11.001","volume":"128","author":"MM Sun","year":"2021","unstructured":"Sun MM, Kelly SP, Mylavarapu AL, Holland GN, Coleman AL, Yu F, Hsu S, Lum F, Gordon LK (2021) Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the american academy of ophthalmology intelligent research in sight registry. Ophthalmology 128:910\u2013919. https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.001","journal-title":"Ophthalmology"},{"key":"6350_CR101","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","volume":"105","author":"BH Fortes","year":"2021","unstructured":"Fortes BH, Liou H, Dalvin LA (2021) Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol 105:1263\u20131271. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316970","journal-title":"Br J Ophthalmol"},{"key":"6350_CR102","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ajo.2020.12.013","volume":"224","author":"D Braun","year":"2021","unstructured":"Braun D, Getahun D, Chiu VY, Coleman AL, Holland GN, Yu F, Gordon LK, Sun MM (2021) Population-based frequency of ophthalmic adverse events in melanoma, other cancers, and after immune checkpoint inhibitor treatment. Am J Ophthalmol 224:282\u2013291","journal-title":"Am J Ophthalmol"},{"key":"6350_CR103","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/iae.0000000000002181","volume":"38","author":"LA Dalvin","year":"2018","unstructured":"Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA (2018) Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina 38:1063\u20131078. https:\/\/doi.org\/10.1097\/iae.0000000000002181","journal-title":"Retina"},{"key":"6350_CR104","unstructured":"Bristol Myers Squibb Company (2020) Yervoy (Ipilimumab) [package insert]. U.S. Food and Drug Administration Website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125377s110lbl.pdf Accessed 1 Mar 2022"},{"key":"6350_CR105","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19:254\u2013267. https:\/\/doi.org\/10.1038\/s41571-022-00600-w","journal-title":"Nat Rev Clin Oncol"},{"key":"6350_CR106","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/jco.2012.44.6112","volume":"31","author":"A Ribas","year":"2013","unstructured":"Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:616\u2013622. https:\/\/doi.org\/10.1200\/jco.2012.44.6112","journal-title":"J Clin Oncol"},{"key":"6350_CR107","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona S, Diamandis EP, Blasutig IM (2016) Cancer immunotherapy: the beginning of the end of cancer? BMC Med 14:73. https:\/\/doi.org\/10.1186\/s12916-016-0623-5","journal-title":"BMC Med"},{"issue":"Suppl 4","key":"6350_CR108","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1634\/theoncologist.13-S4-2","volume":"13","author":"JD Wolchok","year":"2008","unstructured":"Wolchok JD, Saenger Y (2008) The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13(Suppl 4):2\u20139. https:\/\/doi.org\/10.1634\/theoncologist.13-S4-2","journal-title":"Oncologist"},{"key":"6350_CR109","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/09273948.2020.1773867","volume":"30","author":"D Bomze","year":"2022","unstructured":"Bomze D, Meirson T, Ali OH, Goldman A, Flatz L, Habot-Wilner Z (2022) Ocular adverse events induced by immune checkpoint inhibitors: a comprehensive pharmacovigilance analysis. Ocul Immunol Inflamm 30:191\u2013197. https:\/\/doi.org\/10.1080\/09273948.2020.1773867","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"6350_CR110","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1177\/1078155217744872","volume":"25","author":"KJ Williams","year":"2019","unstructured":"Williams KJ, Grauer DW, Henry DW, Rockey ML (2019) Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors. J Oncol Pharm Pract 25(3):544\u2013550","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"6350_CR111","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/WNO.0000000000001148","volume":"41","author":"MM Sun","year":"2021","unstructured":"Sun MM, Seleme N, Chen JJ, Zekeridou A, Sechi E, Walsh RD, Beebe JD, Sabbagh O, Mejico LJ, Gratton S, Skidd PM, Bellows DA, Falardeau J, Fraser CL, Cappelen-Smith C, Haines SR, Hassanzadeh B, Seay MD, Subramanian PS, Williams Z, Gordon LK (2021) Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1\/PD-L1 checkpoint blockade. J Neuro-ophthalmol 41(4):519\u2013530","journal-title":"J Neuro-ophthalmol"},{"key":"6350_CR112","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99:4078\u20134085. https:\/\/doi.org\/10.1210\/jc.2014-2306","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6350_CR113","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","volume":"181","author":"A Faje","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen JV, Sullivan RJ, Nachtigall L, Tritos N (2019) Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol 181(3):211\u2013219","journal-title":"Eur J Endocrinol"},{"key":"6350_CR114","doi-asserted-by":"crossref","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J ImmunoTherapy Cancer 7(1) (no pagination)","DOI":"10.1186\/s40425-019-0617-x"},{"key":"6350_CR115","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/bjophthalmol-2020-317060","volume":"106","author":"T Xia","year":"2022","unstructured":"Xia T, Brucker AJ, McGeehan B, VanderBeek BL (2022) Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database. Br J Ophthalmol 106:87\u201390. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317060","journal-title":"Br J Ophthalmol"},{"key":"6350_CR116","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/wnl.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127\u20131134. https:\/\/doi.org\/10.1212\/wnl.0000000000004359","journal-title":"Neurology"},{"key":"6350_CR117","doi-asserted-by":"crossref","unstructured":"Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'Ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J ImmunoTherapy of Cancer 7(1) (no pagination)","DOI":"10.1186\/s40425-019-0774-y"},{"issue":"8 S","key":"6350_CR118","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1097\/RHU.0000000000001012","volume":"27","author":"AE Betrains","year":"2021","unstructured":"Betrains AE, Blockmans DE (2021) Immune checkpoint inhibitor-associated polymyalgia rheumatica\/giant cell arteritis occurring in a patient after treatment with nivolumab. J Clin Rheumatol 27(8 S):S555\u2013S556","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"6350_CR119","first-page":"87","volume":"25","author":"KL Chow","year":"2020","unstructured":"Chow KL, Perju-Dumbrava L, Malhotra A, Olesen I, Briggs P (2020) Giant cell arteritis secondary to combined nivolumab and ipilimumab in metastatic pleural mesothelioma. Neurology Asia 25(1):87\u201388","journal-title":"Neurology Asia"},{"key":"6350_CR120","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/art.38282","volume":"66","author":"BL Goldstein","year":"2014","unstructured":"Goldstein BL, Gedmintas L, Todd DJ (2014) Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 66:768\u2013769. https:\/\/doi.org\/10.1002\/art.38282","journal-title":"Arthritis Rheumatol"},{"key":"6350_CR121","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1093\/annonc\/mdx306","volume":"28","author":"I Micaily","year":"2017","unstructured":"Micaily I, Chernoff M (2017) An unknown reaction to pembrolizumab: giant cell arteritis. Ann Oncol 28:2621\u20132622. https:\/\/doi.org\/10.1093\/annonc\/mdx306","journal-title":"Ann Oncol"},{"key":"6350_CR122","doi-asserted-by":"crossref","unstructured":"Miano DI, Cosgrove R, Sherman J, Balaraman S, Sherman M (2022) Pembrolizumab-induced giant cell arteritis in the setting of urothelial carcinoma. Neuro Ophthalmol","DOI":"10.1080\/01658107.2022.2108847"},{"key":"6350_CR123","doi-asserted-by":"publisher","unstructured":"Cadena RH, Reitsema RD, Huitema MG, van Sleen Y, van der Geest KSM, Heeringa P, Boots AMH, Abdulahad WH, Brouwer E (2019) Decreased expression of negative immune checkpoint VISTA by CD4+T cells facilitates T helper 1, T helper 17, and T follicular helper lineage differentiation in GCA. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.01638","DOI":"10.3389\/fimmu.2019.01638"},{"key":"6350_CR124","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69:837\u2013845. https:\/\/doi.org\/10.1002\/art.40044","journal-title":"Arthritis Rheumatol"},{"key":"6350_CR125","doi-asserted-by":"publisher","first-page":"E76","DOI":"10.1200\/jco.2011.38.7886","volume":"30","author":"M Maur","year":"2012","unstructured":"Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P (2012) Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 30:E76\u2013E78. https:\/\/doi.org\/10.1200\/jco.2011.38.7886","journal-title":"J Clin Oncol"},{"issue":"5","key":"6350_CR126","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ccr3.2122","volume":"7","author":"D Kim","year":"2019","unstructured":"Kim D (2019) Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer. Clin Case Rep 7(5):935\u2013938","journal-title":"Clin Case Rep"},{"key":"6350_CR127","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1212\/cpj.0000000000000362","volume":"7","author":"HM Hussein","year":"2017","unstructured":"Hussein HM, Dornfeld B, Schneider DJ (2017) Nivolumab-induced posterior reversible encephalopathy syndrome. Neurol Clin Pract 7:455\u2013456. https:\/\/doi.org\/10.1212\/cpj.0000000000000362","journal-title":"Neurol Clin Pract"},{"key":"6350_CR128","doi-asserted-by":"crossref","unstructured":"Sabile JM, Grider DJ, Prickett KA, Li H, Mallidi PV (2021) Posterior reversible encephalopathy syndrome (PRES) and drug-induced hypersensitivity syndrome (DIHS) following immunotherapy and BRAF\/MEK inhibition with continued response in metastatic melanoma. Case Rep Oncol Med 2021 (no pagination)","DOI":"10.1155\/2021\/8845063"},{"key":"6350_CR129","doi-asserted-by":"crossref","unstructured":"Foulser PFG, Senthivel N, Downey K, Hart PE, McGrath SE (2022) Posterior reversible encephalopathy syndrome associated with use of atezolizumab for the treatment of relapsed triple negative breast cancer. Cancer Treat Res Commun 31 (no pagination)","DOI":"10.1016\/j.ctarc.2022.100548"},{"issue":"7","key":"6350_CR130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.nrl.2020.08.009","volume":"36","author":"A Lambea-Gil","year":"2021","unstructured":"Lambea-Gil A, Sancho-Saldana A, Caldu-Agud R, Garcia-Rubio S (2021) Posterior reversible encephalopathy associated with pembrolizumab. Neurologia (Barcelona, Spain) 36(7):548\u2013550","journal-title":"Neurologia (Barcelona, Spain)"},{"key":"6350_CR131","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.brainresbull.2017.03.012","volume":"131","author":"Z Chen","year":"2017","unstructured":"Chen Z, Shen GQ, Lerner A, Gao B (2017) Immune system activation in the pathogenesis of posterior reversible encephalopathy syndrome. Brain Res Bull 131:93\u201399. https:\/\/doi.org\/10.1016\/j.brainresbull.2017.03.012","journal-title":"Brain Res Bull"},{"key":"6350_CR132","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74:1216\u20131222. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"issue":"7","key":"6350_CR133","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2019.01.031","volume":"126","author":"JM Kim","year":"2019","unstructured":"Kim JM, Materin MA, Sznol M, Kluger HM, Weiss S, Chow J, Stoessel K, Kombo N, Del Priore L, Pointdujour-Lim R (2019) Ophthalmic immune-related adverse events of immunotherapy: a single-site case series. Ophthalmology 126(7):1058\u20131062","journal-title":"Ophthalmology"},{"issue":"7","key":"6350_CR134","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00415-018-8890-z","volume":"265","author":"S Mancone","year":"2018","unstructured":"Mancone S, Lycan T, Ahmed T, Topaloglu U, Dothard A, Petty WJ, Strowd RE (2018) Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J Neurol 265(7):1636\u20131642","journal-title":"J Neurol"},{"issue":"3","key":"6350_CR135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/01658107.2019.1566385","volume":"44","author":"KA Jaben","year":"2020","unstructured":"Jaben KA, Francis JH, Shoushtari AN, Abramson DH (2020) Isolated abducens nerve palsy following pembrolizumab. Neuro-Ophthalmology 44(3):182\u2013185","journal-title":"Neuro-Ophthalmology"},{"issue":"1","key":"6350_CR136","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger B, Zwaan CM, Marshall LV, Michon J, Bourdeaut F, Casanova M, Corradini N, Rossato G, Farid-Kapadia M, Shemesh CS, Hutchinson KE, Donaldson F, Liao M, Caron H, Trippett T (2020) Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1\u20132 study. Lancet Oncol 21(1):134\u2013144","journal-title":"Lancet Oncol"},{"key":"6350_CR137","doi-asserted-by":"crossref","unstructured":"Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Goppner D, Dummer R, Heinzerling LM (2013) The Price of Tumor Control: an Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 8(1) (no pagination)","DOI":"10.1371\/journal.pone.0053745"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06350-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06350-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06350-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T14:09:52Z","timestamp":1720015792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06350-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":137,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6350"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06350-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"20 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No patients were involved in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}